Zoster, Purified Antigen Vaccine (Recombinant)

Not Applicable

10/02/2025 Recombinant zoster vaccine for the prevention of herpes zoster and post-herpetic neuralgia

The Ministry of Health’s Drug Advisory Committee has recommended:

• Recombinant varicella zoster virus glycoprotein E 50 mcg/0.5 mL powder and suspension for suspension for injection for the prevention of herpes zoster (HZ) and post-herpetic neuralgia in:

  • adults 60 years of age or older; and

  • adults 18 years of age or older at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

Funding status

[R] Recombinant varicella zoster virus glycoprotein E 50 mcg/0.5 mL powder and suspension for suspension for injection is recommended for inclusion on the MOH Subsidised Vaccine List (SVL) for the abovementioned indication from September 2025.

[R] The recombinant varicella zoster virus glycoprotein E injection should be used in line with the additional clinical criteria listed in the Annex.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration